INMB: INmune Bio, Inc. Stock

by  •  • Comments Off on INMB: INmune Bio, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 220.73
Enterprise Value ($M) 202.98
Book Value ($M) 29.02
Book Value / Share 1.47
Price / Book 7.61
NCAV ($M) 12.01
NCAV / Share 0.61
Price / NCAV 18.37

Profitability (mra)
Return on Invested Capital (ROIC) -0.93
Return on Assets (ROA) -0.47
Return on Equity (ROE) -0.62

Liquidity (mrq)
Quick Ratio 1.71
Current Ratio 1.71

Balance Sheet (mrq) ($M)
Current Assets 29.82
Assets 46.83
Liabilities 17.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.15
Operating Income -29.74
Net Income -30.01
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -11.98
Cash from Investing 0.00
Cash from Financing -4.22

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT P
2024-04-16 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UN
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15
2023-11-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPO
2023-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 ☐ TRANSITION REPORT PU

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-17 11,739 79,747 14.72
2024-05-16 10,012 22,051 45.40
2024-05-15 27,235 138,421 19.68
2024-05-14 26,228 105,144 24.94
2024-05-13 33,727 154,536 21.82

(click for more detail)

Similar Companies
INDP – Indaptus Therapeutics, Inc. INKT – MiNK Therapeutics, Inc.
INM – InMed Pharmaceuticals Inc. INTS – Intensity Therapeutics, Inc.
ITRM – Iterum Therapeutics plc


Financial data and stock pages provided by
Fintel.io